Sangamo Therapeutics Inc. buy agenda2020
Summary
This prediction ended on 26.09.14 with a price of €8.72. The prediction for Sangamo Therapeutics Inc. disappointed with a performance of -10.97%. agenda2020 has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sangamo Therapeutics Inc. | -7.337% | -7.337% | 2.048% | -91.143% |
| iShares Core DAX® | 1.056% | 1.056% | 18.108% | 16.006% |
| iShares Nasdaq 100 | -1.886% | -0.160% | 26.970% | 36.233% |
| iShares Nikkei 225® | 2.553% | 4.359% | 17.676% | 10.955% |
| iShares S&P 500 | -0.434% | 0.224% | 24.986% | 37.667% |
Comments by agenda2020 for this prediction
In the thread Sangamo Bioscienes diskutieren
pipeline gut, chart schlecht
Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene.
Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."
Stopped prediction by agenda2020 for Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc.
14.10.19
25.10.19
25.10.19
